Skip to main content

Table 5 Treatment response of chronic ITP patients with IFN-γ and IFN-γR

From: The cytokine polymorphisms affecting Th1/Th2 increase the susceptibility to, and severity of, chronic ITP

  IFN-γ AA IFN-γ non-AA   IFN-γR AA IFN-γR non-AA  
N (%) N (%) P value OR 95% CI N (%) N (%) P value OR 95%
All treatment, no. of cases (%) 82 (75.9) 15 (83.3) 0.76 0.66 0.18–2.48 89 (77.4) 8 (72.7) 0.71 1.35 0.33–5.47
 Second line treatment, no. of cases (%) 33 (30.6) 4 (22.2) 0.58 1.54 0.47–5.03 33 (28.7) 4 (36.4) 0.73 0.70 0.19–2.57
Second line treatment, no. of cases (%)
 CR, no. of cases (%) 57 (69.5) 11 (73.3) 1.00 0.83 0.24–2.86 64 (71.9) 4 (50.0) 0.23 2.56 0.59–11.03
 RR (CR+R), no. of cases (%) 79 (96.3) 13 (86.7) 0.17 4.05 0.62–26.62 85 (95.5) 7 (87.5) 0.36 3.04 0.30–30.98
Prednisolone therapy, no. of cases (%) 68 (63.0) 14 (77.8) 0.29 0.49 0.15–1.58 76 (66.1) 6 (54.5) 0.51 1.62 0.47–5.66
Response to prednisolone therapy
 CR, no. of cases (%) 37 (54.4) 8 (57.1) 1.00 0.90 0.28–2.86 42 (55.3) 3 (50.0) 1.00 1.24 0.23–6.52
 RR (CR+R), no. of cases (%) 63 (92.6) 11 (78.6) 0.13 3.44 0.72–16.49 68 (89.5) 6 (100) 1.00   
Splenectomy, no. of cases (%) 17 (15.7) 2 (11.1) 1.00 1.50 0.32–7.10 18 (15.7) 1 (9.1) 1.00 1.86 0.22–15.40
Response to splenectomy
 CR, no. of cases (%) 10 (58.8) 1 (50.0) 1.00 1.43 0.08–26.90 11 (61.1) 0 (0) 0.42   
 RR (CR+R), no. of cases (%) 13 (76.5) 1 (50.0) 0.47 3.25 0.16–64.61 14 (77.8) 0 (0) 0.26   
Eradication of Helicobacter pylori, no. of cases (%) 40 (37.0) 3 (16.7) 0.11 3.03 0.83–11.12 38 (33.0) 5 (45.5) 0.51 0.61 0.17–2.12
Response to eradication of Helicobacter pylori
 CR, no. of cases (%) 19 (47.5) 1 (33.3) 1.00 1.81 0.15–21.59 17 (44.7) 3 (60.0) 0.65 0.54 0.08–3.61
Severe ITP, no. of cases (%) 23 (21.3) 1 (5.6) 0.19 4.60 0.58–36.41 22 (19.1) 2 (18.2) 1.00 1.07 0.22–5.28
Refractory ITP, no. of cases (%) 9 (8.3) 1 (5.6) 1.00 1.55 0.18–12.99 9 (7.8) 1 (9.1) 1.00 0.85 0.10–7.40
Corticosteroid-dependent, no. of cases (%) 30 (28.8) 7 (41.2) 0.40 0.58 0.20–1.66 35 (30.4) 2 (18.2) 0.72 1.84 0.37–9.13
  1. Second line treatment: Patients in need of second line, CR (complete response): platelet count of at least 100 × 109/L, R (response): platelet count between 30 and 100 × 109/L and at least double the baseline count, severe ITP: presence of bleeding symptoms at presentation sufficient to mandate treatment, or occurrence of new bleeding symptoms requiring additional therapeutic intervention with a different platelet-enhancing agent or an increased dose, refractory ITP: failure to achieve at least R or loss of R after splenectomy, loss of R: platelet count 30 × 109/L or a less than 2-fold increase in platelet count from baseline or the presence of bleeding, corticosteroid-dependence: the ongoing need for continuous corticosteroid administration or frequent courses of corticosteroids to maintain a platelet count at or above 30 × 109/L and/or to avoid bleeding.
  2. ITP immune thrombocytopenia, IFN interferon, IL interleukin, OR odds ratio, CI confidence interval, SD standard deviation